DNA Script $2.7M toegekend in innovatiesubsidies van Bpifrance – Totale financiering tot op heden gestegen tot $27M

PARIJS –(BUSINESS WIRE)–

Deze nieuwe subsidie zal worden besteed aan de ontwikkeling van het platform van het bedrijf voor de biomanufacturing van lange DNA-constructies voor cel- en gentherapie toepassingen.

DNA Script kondigde vandaag aan dat het $ 2,7M aan niet-verwaterende financiering heeft gekregen van het “Concours d’Innovation” programma van Bpifrance. DNA Script kreeg deze financiering, te ontvangen als subsidies en terugbetaalbare voorschotten, op basis van de belofte van de innovatieve enzymatische DNA synthese technologie van het bedrijf en op het potentieel van het bedrijf om een wereldwijde leider te worden in de biomanufacturing voor cel-en gentherapie.

Naarmate de genomica in een stroomversnelling komt, wordt het onderzoek op het gebied van de biowetenschappen gestimuleerd door innovatieve genoombewerkingstechnologieën. De markt voor synthetische nucleïnezuren is wereldwijd gegroeid tot meer dan 1 miljard dollar per jaar, maar aan de vraag wordt niet altijd voldaan. De afgelopen 50 jaar is synthetisch DNA vervaardigd door middel van een complex chemisch proces met beperkingen op het gebied van kwaliteit, doorlooptijd en productieflexibiliteit. DNA Script daarentegen introduceert een nieuw biochemisch proces voor DNA- en RNA-synthese gebaseerd op het gebruik van zeer efficiënte enzymen. Deze technologie bootst de manier na waarop de natuur genetische code produceert en maakt betere prestaties mogelijk terwijl het gebruik van agressieve chemicaliën tot een minimum wordt beperkt. Het zal met name de productie van lange DNA-constructies mogelijk maken, die een sleutelcomponent vormen van geneesmiddelen voor cel- en gentherapie.

DNA Script Awarded $2.7M in Innovation Grants From Bpifrance — Total Financing Raised to Date Is $27M

PARIS –(BUSINESS WIRE)–

This new grant will be dedicated to the development of the company’s platform for biomanufacturing long DNA constructs for cell and gene therapy applications

DNA Script announced today it has been awarded $2.7M in non-dilutive financing from the “Concours d’Innovation” program of Bpifrance. DNA Script was awarded this financing, to be received as subsidies and refundable advances, based on the promise of the company’s innovative enzymatic DNA synthesis technology and on the company’s potential to become a global leader in biomanufacturing for cell and gene therapy.

As the field of genomics accelerates, innovative genome editing technologies are driving advancements in life sciences research. The market for synthetic nucleic acids has expanded to over $1 billion per year globally, but the demand is not always met. For the past 50 years, synthetic DNA has been manufactured through a complex chemical process with limitations in terms of quality, turn-around time and manufacturing flexibility. In contrast, DNA Script introduces a novel biochemical process for DNA and RNA synthesis based on the use of highly efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals. It will in particular enable the production of long DNA constructs, which are a key component of cell and gene therapy drugs.

“In the past few years, cell and gene therapy, as well as gene editing approaches, have showed promising results in the clinic. However, manufacturing such drugs is often a challenge. There is an unmet need for high quality, quickly manufactured synthetic DNA. Through this new financing, BPIFrance will enable the company to further demonstrate the potential of the technology for manufacturing long DNA constructs at scale,” said Thomas Ybert, PhD, CEO and co-founder of DNA Script.

“We are proud to support DNA Script in the development of this technology. This young French company has everything it needs to become a world leader in this extremely promising field,” said Virginie Fontaine from Bpifrance.

DNA Script is one of eight companies to receive an award for the “Concours d’Innovation 2018” of Bpifrance in the “Healthcare” division. This competitive grant is dedicated to innovative projects aimed at accelerating the emergence of companies with the potential to become world leaders in their respective markets.

Ybert added: “We see our project to set a gold standard for efficient, clean DNA synthesis as a great example of several high-value applications which will benefit from DNA Script’s core platform technology in the coming years.”

To date, DNA Script has raised a total of $27M. In September 2017, DNA Script announced a Series A financing round of $13 million led by Illumina Ventures, with additional investments from M Ventures — the corporate venture arm of Merck KGaA, Darmstadt, Germany — and existing investors Sofinnova Partners, Kurma Partners and Idinvest Partners.

About DNA Script

Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script’s approach leverages billions of years of natural evolution to enable genome-scale synthesis. The company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops and DNA data storage. www.dnascript.co

About Bpifrance

A subsidiary of the Caisse des Dépôts (French Consignments and Loans Fund) and the State, a trusted partner of entrepreneurs, Bpifrance supports companies from start-up to stock exchange listing, with credit, collateral and equity. Bpifrance also provides support services and enhanced support for innovation, acquisitions and exports, in partnership with Business France. Bpifrance offers companies a continuum of funding at each key stage of their development and an offer adapted to regional specificities. With 47 regional offices (90% of its decisions are taken at the regional level) Bpifrance is a tool of economic competitiveness for entrepreneurs. Bpifrance supports public policies pursued by the French State and by Regional Councils to meet three objectives: support the growth of businesses; prepare future competitiveness; contribute to the development of a favorable ecosystem for entrepreneurship. With Bpifrance, companies benefit from an influential, available and effective intermediary to meet all their needs in terms of finance, innovation and investment.

For further information, please visit: www.bpifrance.fr

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005115/en/

Contacts

Press contact in the US
Seismic
Lisa Rodriguez, 415-505-5447
lisa@teamseismic.com
or
Press contacts in Europe
ALIZE RP
Caroline Carmagnol and Tatiana Vieira, 06 64 18 99 59 / 01 44 54 36 65
DNASCRIPT@alizerp.com
or
DNA Script Contact
Sylvain Gariel, COO
sg@dnascript.co